These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19194317)

  • 1. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
    Apuzzo LG; Vaida F; Gallant JE; Ernstrom KB; Little SJ; Routy JP; Collier AC; Conway B; Markowitz MH; Hecht FM; Walker BD; Connick E; Margolick JB
    J Acquir Immune Defic Syndr; 2009 Mar; 50(3):267-75. PubMed ID: 19194317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Chou R; Fu R; Huffman LH; Korthuis PT
    Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.
    Klein MB; Willemot P; Murphy T; Lalonde RG
    AIDS; 2004 Sep; 18(14):1895-904. PubMed ID: 15353975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
    Floridia M; Bucciardini R; Fragola V; Galluzzo CM; Giannini G; Pirillo MF; Amici R; Andreotti M; Ricciardulli D; Tomino C; Vella S;
    HIV Med; 2004 Jan; 5(1):1-10. PubMed ID: 14731162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes].
    de la Torre J; Santos J; Perea-Milla E; Pérez I; Moreno F; Palacios R; Santamaría S; Del Arco A; Nuño E; Godoy M; Prada JL; Olalla J; Aguilar J; Martos F;
    Enferm Infecc Microbiol Clin; 2008; 26(7):416-22. PubMed ID: 18842236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.
    Weiser SD; Guzman D; Riley ED; Clark R; Bangsberg DR
    HIV Clin Trials; 2004; 5(5):278-87. PubMed ID: 15562368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.